

# Mutsa Tatenda Madondo

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2854050/publications.pdf>

Version: 2024-02-01

7  
papers

1,198  
citations

1307594

7  
h-index

1720034

7  
g-index

7  
all docs

7  
docs citations

7  
times ranked

2292  
citing authors

| # | ARTICLE   | IF   | CITATIONS |
|---|---|------|-----------|
| 1 | Enterococcus hirae and Bacteroides fragilis Facilitate Cyclophosphamide-Induced Therapeutic Immunomodulatory Effects. <i>Immunity</i> , 2016, 45, 931-943.  | 14.3 | 645       |
| 2 | Paclitaxel and Its Evolving Role in the Management of Ovarian Cancer. <i>BioMed Research International</i> , 2015, 2015, 1-21.  | 1.9  | 227       |
| 3 | Low dose cyclophosphamide: Mechanisms of T cell modulation. <i>Cancer Treatment Reviews</i> , 2016, 42, 3-9.  | 7.7  | 117       |
| 4 | Impaired Th1 immunity in ovarian cancer patients is mediated by TNFR2+ Tregs within the tumor microenvironment. <i>Clinical Immunology</i> , 2013, 149, 97-110.   | 3.2  | 108       |
| 5 | Interleukin 6 Present in Inflammatory Ascites from Advanced Epithelial Ovarian Cancer Patients Promotes Tumor Necrosis Factor Receptor 2-Expressing Regulatory T Cells. <i>Frontiers in Immunology</i> , 2017, 8, 1482. | 4.8  | 53        |
| 6 | Pre-operative sera interleukin-6 in the diagnosis of high-grade serous ovarian cancer. <i>Scientific Reports</i> , 2020, 10, 2213.  | 3.3  | 37        |
| 7 | Sperm Protein 17 Expression by Murine Epithelial Ovarian Cancer Cells and Its Impact on Tumor Progression. <i>Cancers</i> , 2018, 10, 276.  | 3.7  | 11        |